Intriguingly, USP10 inhibition has been shown to promote oncoprotein FLT3 degradation, suggesting that USP10 could be considered as a potential pharmacological target for fighting FLT3- mutant AML disease [73]. Here, USP10 is linked to acute myeloid leukemia.